The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase inhibitors

Cancer Genetics

Volumn 207, Issue 5, 2014, Pages 171-176

  Theil, Karl S ^a   Cotta, Claudiu V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Blast crisis; Clonal evolution; Inv(3); Philadelphia chromosome; T(9; 22)

Indexed keywords

HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CASE REPORT; CHROMOSOME 22Q; CHROMOSOME 3Q; CHROMOSOME 9Q; CHROMOSOME INVERSION; CHROMOSOME INVERSION 3; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; DEATH; DRUG RESPONSE; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

BLAST CRISIS; CLONAL EVOLUTION; INV(3); PHILADELPHIA CHROMOSOME; T(9;22);

AGED; BLAST CRISIS; CHROMOSOME INVERSION; CHROMOSOMES, HUMAN, PAIR 3; FATAL OUTCOME; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PROTEIN KINASE INHIBITORS; TRANSLOCATION, GENETIC;

EID: 84904733882     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.05.006     Document Type: Article

References (13)

1. Cortes J.E., Talpaz M., Giles F., et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003, 101:3794-3800.
2. Secker-Walker L.M., Mehta A., Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995, 91:490-501.
3. Cui W., Sun J., Cotta C.V., et al. Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. Am J Clin Pathol 2011, 136:282-288.
4. Sun J., Konoplev S.N., Wang X., et al. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. Mod Pathol 2011, 24:384-389.
5. ISCN 2013: an international system for human cytogenetic nomenclature 2013, Karger, Basel, NY. L.G. Shaffer, J. McGowan-Jordan, M. Schmid (Eds.).
6. Han J.Y., Theil K.S. The Philadelphia chromosome as a secondary abnormality in inv(3)(q21q26) acute myeloid leukemia at diagnosis: confirmation of p190 BCR-ABL mRNA by real-time quantitative polymerase chain reaction. Cancer Genet Cytogenet 2006, 165:70-74.
7. Paquette R.L., Nicoll J., Chalukya M., et al. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genet 2011, 204:392-397.
8. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer (IARC), Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
9. Konoplev S., Yin C.C., Kornblau S.M., et al. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma 2013, 54:138-144.
10. Merzianu M., Medeiros L.J., Cortes J., et al. inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. Am J Clin Pathol 2005, 124:807-814.
11. Roth C.G., Contis L., Gupta S., et al. De novo acute myeloid leukemia with Philadelphia chromosome (BCR-ABL) and inversion 16 (CBFB-MYH11): report of two cases and review of the literature. Leuk Lymphoma 2011, 52:531-535.
12. Yin C.C., Medeiros L.J., Glassman A.B., et al. t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia. Am J Clin Pathol 2004, 121:836-842.
13. Castaigne S., Berger R., Jolly V., et al. Promyelocytic blast crisis of chronic myelocytic leukemia with both t(9;22) and t(15;17) in M3 cells. Cancer 1984, 54:2409-2413.